Shares of Nantkwest Inc (NASDAQ:NK) saw unusually-high trading volume on Tuesday . Approximately 863,506 shares traded hands during mid-day trading, an increase of 210% from the previous session’s volume of 278,145 shares.The stock last traded at $1.33 and had previously closed at $1.22.
NK has been the subject of a number of recent research reports. ValuEngine cut shares of Nantkwest from a “buy” rating to a “hold” rating in a research report on Friday, January 4th. Citigroup raised shares of Nantkwest from a “sell” rating to a “neutral” rating and reduced their target price for the company from $3.00 to $2.00 in a research report on Friday, November 30th. Finally, Zacks Investment Research raised shares of Nantkwest from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research report on Thursday. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $2.33.
The stock has a market cap of $104.40 million, a PE ratio of -1.12 and a beta of 2.71. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.26 and a current ratio of 3.26.
A number of institutional investors and hedge funds have recently bought and sold shares of NK. Candriam Luxembourg S.C.A. bought a new stake in Nantkwest during the fourth quarter worth about $270,000. Renaissance Technologies LLC lifted its position in Nantkwest by 34.6% during the third quarter. Renaissance Technologies LLC now owns 700,567 shares of the biotechnology company’s stock worth $2,592,000 after purchasing an additional 180,167 shares during the period. D. E. Shaw & Co. Inc. lifted its position in Nantkwest by 338.7% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 180,595 shares of the biotechnology company’s stock worth $210,000 after purchasing an additional 139,431 shares during the period. Bridgeway Capital Management Inc. lifted its position in Nantkwest by 75.0% during the third quarter. Bridgeway Capital Management Inc. now owns 175,000 shares of the biotechnology company’s stock worth $648,000 after purchasing an additional 75,000 shares during the period. Finally, Two Sigma Investments LP bought a new stake in Nantkwest during the fourth quarter worth about $84,000. 10.83% of the stock is owned by institutional investors and hedge funds.
Nantkwest Company Profile (NASDAQ:NK)
NantKwest, Inc, a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.
Recommended Story: Day Trading
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.